Skip to content

AQSE company news

2025-12-01

Back to news

Aquis Stock Exchange Weekly Highlights 01.12.25

0

Published:

December 1, 2025

Most recent

Sulnox Group PLC announced a long-term distribution agreement with Drew Marine USA, Inc., a large supplier of performance chemicals and fuel management services to the maritime industry, that has a presence in over 1,200 ports globally.
Ben Richardson, CEO, said: “Drew Marine has a huge presence globally, representing a very sizeable opportunity for Sulnox. Critically, it is an organisation that understands extremely well the value of our products to all types of maritime user needing to achieve greater fuel efficiency and progress in decarbonisation, with no capital outlay or disruption.” Read more
IntelliAM AI PLC announced that it has raised £250,000 through the placing of new ordinary shares. Read more
The Company further announced it has won new contracts and platform deployments in the building products sector, a new business vertical, with manufacturers including Tarmac, Marshalls, H+H Building Construction, and Knauf in the UK and Japan. Read more
Valereum Plc has entered into a legally binding heads of terms agreement to raise USD $200m of Royalty and Streaming capital from Valereum QGP-SP for a stake of up to 49.9% of the Company.
Gary Cottle, Group CEO, commented: “These funds, and further debt and equity that are available working with QGP as a strategic capital partner, will be deployed to build out our Digital Asset Treasury program, a full stack Tokenisation ecosystem that has been thoroughly endorsed by QGP.” Read more
NYCE International PLC announced that its venture division, NYCE Ventures, has entered a post-revenue phase following the launch and commercial activation of its first two operating subsidiaries, Nirmata Play and ClickSpin Media. Read more
Ananda Pharma plc aannounced that its first-in-human clinical trial has shown that its MRX1 investigational product demonstrates a favourable safety profile.
Melissa Sturgess, CEO, said: “Ananda is now a clinical stage biotech with its lead drug candidate MRX1 demonstrating a favourable safety profile. The team is delighted with this result and looks forward to keeping shareholders updated with the full Phase 1 study readout which remains on track for delivery in Quarter 2, 2026.” Read more
Cooks Coffee Company Limited reported its results for the six months ended 30 September 2025. The Group highlighted that its revenue increased by 111% to approximately £2.5m (2025: £1.1m), total UK and Ireland store sales increased by 26.9% to £19.7m, and 11 stores were opened. Read more
Back to news

Company

  • About
  • News
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal